Stryker Corporation $SYK Shares Sold by Commerzbank Aktiengesellschaft FI

Commerzbank Aktiengesellschaft FI trimmed its position in Stryker Corporation (NYSE:SYK) by 15.2% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 23,137 shares of the medical technology company’s stock after selling 4,143 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Stryker were worth $8,132,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of SYK. United Financial Planning Group LLC acquired a new stake in Stryker in the 3rd quarter worth about $27,000. CGC Financial Services LLC acquired a new stake in Stryker in the 4th quarter worth about $29,000. Strive Asset Management LLC acquired a new stake in Stryker in the 3rd quarter worth about $30,000. ANTIPODES PARTNERS Ltd acquired a new stake in Stryker in the 3rd quarter worth about $34,000. Finally, Copia Wealth Management boosted its holdings in Stryker by 181.6% in the 3rd quarter. Copia Wealth Management now owns 107 shares of the medical technology company’s stock worth $40,000 after buying an additional 69 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Stryker Trading Up 0.4%

Shares of Stryker stock opened at $306.74 on Friday. The stock has a market cap of $117.59 billion, a P/E ratio of 35.50, a P/E/G ratio of 1.92 and a beta of 0.80. The stock’s 50 day simple moving average is $329.68 and its 200-day simple moving average is $351.73. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Analysts predict that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. BTIG Research lowered their target price on Stryker from $397.00 to $379.00 and set a “buy” rating on the stock in a report on Friday, May 1st. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Citigroup lowered their target price on Stryker from $420.00 to $385.00 and set a “buy” rating on the stock in a report on Tuesday, April 7th. Jefferies Financial Group restated a “buy” rating and set a $465.00 target price on shares of Stryker in a report on Wednesday, March 4th. Finally, Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $395.48.

Insider Transactions at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at $50,170.65. The trade was a 95.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is currently owned by insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.